Travere Therapeutics (TVTX) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Travere Therapeutics (TVTX) over the last 16 years, with Q4 2024 value amounting to $4000.0.
- Travere Therapeutics' Income towards Parent Company rose 10025.36% to $4000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $4000.0, marking a year-over-year increase of 10015.77%. This contributed to the annual value of -$915000.0 for FY2024, which is 10034.54% down from last year.
- Latest data reveals that Travere Therapeutics reported Income towards Parent Company of $4000.0 as of Q4 2024, which was up 10025.36% from -$100000.0 recorded in Q3 2024.
- Travere Therapeutics' Income towards Parent Company's 5-year high stood at $240.0 million during Q3 2023, with a 5-year trough of -$121.6 million in Q4 2020.
- In the last 5 years, Travere Therapeutics' Income towards Parent Company had a median value of -$101500.0 in 2024 and averaged -$3.5 million.
- Per our database at Business Quant, Travere Therapeutics' Income towards Parent Company crashed by 657439.9% in 2021 and then skyrocketed by 156569.03% in 2023.
- Travere Therapeutics' Income towards Parent Company (Quarter) stood at -$121.6 million in 2020, then rose by 27.01% to -$88.8 million in 2021, then surged by 122.32% to $19.8 million in 2022, then plummeted by 107.96% to -$1.6 million in 2023, then surged by 100.25% to $4000.0 in 2024.
- Its last three reported values are $4000.0 in Q4 2024, -$100000.0 for Q3 2024, and -$757000.0 during Q2 2024.